Medlinker
Medlinker (医联) operates an AI-native medical platform built around MedGPT, its proprietary large language model. It serves hospitals, pharmaceutical and insurance companies through B2B licensing, and offers free AI-assisted expert consultations to consumers via the Future Doctor app.
- Company typePrivate
- Founded2014
- HeadquartersChengdu, China
- Headcount51–100
- GTM typeB2B and B2C
- OfferingSoftware
What Medlinker does
Medlinker (医联), founded in 2014 by Wang Shirui in Chengdu, operates an AI-native medical platform built around MedGPT, a proprietary medical vertical large language model developed in-house. MedGPT employs a dual-system (fast-slow) architecture intended to suppress LLM hallucinations: a fast system handles intuitive dialogue while a slow system performs logic-based diagnostic reasoning. The model is grounded in 100,000+ medical guidelines, 8 million evidence units, 2,000+ ICD disease categories, 10,000+ clinical rules, and 650+ audit algorithm units co-developed with 120+ Grade 3A hospital experts. MedGPT received China's first CAC deep synthesis algorithm filing for AI diagnosis and treatment recommendations (January 2024) and is validated at 96% consistency with Grade 3A attending physicians in real-world clinical testing.
The product portfolio spans the consumer Future Doctor (未来医生) app and WeChat Mini Program offering 24/7 free expert consultations; DoctorWorks.AI for physician-side clinical support; the AI Institution Cooperation Platform and AI Medical Cooperation Platform for B-end licensing to hospitals; an Insurance Industry Solutions stack with direct billing integration; and 医联通 (Medlinker Connect), a pharma and medical device digital marketing platform. The platform serves 20M+ registered users, 1.5M+ registered doctors (584,000 from Grade 3A hospitals), and operates across 16 Chinese cities with 70+ physical stores. Named hospital deployments include China-Japan Friendship Hospital, Peking University Third Hospital, Jinhua Central Hospital, Nanchong Central Hospital, and Guangzhou Red Cross Hospital; enterprise integrations extend to China Electronics Cloud, China Renaissance Capital, and Omron.
Monetization is anchored in B2B MedGPT licensing to hospitals, pharma and insurance companies on annual subscription contracts (the primary revenue stream), supplemented by pharma advertising spend through 医联通 and revenue from insurance underwriting and claims automation. Future Doctor's free consumer consultations are funded by B-end revenue as a customer acquisition funnel. The company raised approximately $760M+ across disclosed rounds (highlighted by Tencent's $40M Series B in 2015 and Sino Biopharmaceutical's $514M 2021 round) and was named a Hurun Global Unicorn in 2023 (rank 207) and 2024 (rank 216).
Medlinker firmographics
Firmographics- Name
- Medlinker
- Legal name
- Beijing Zhiyi Fangcheng Technology Co.,Ltd. (北京智医方程科技有限公司)
- Website
- https://medlinker.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Medlinker (医联) operates an AI-native medical platform built around MedGPT, its proprietary large language model. It serves hospitals, pharmaceutical and insurance companies through B2B licensing, and offers free AI-assisted expert consultations to consumers via the Future Doctor app.
- Ownership category
- akta.pro rank
Medlinker industry classification
Industry- Product category
- AI Medical Diagnosis Software
- NAICS
- Offices of Physicians (62111), Offices of Physicians (except Mental Health Specialists) (621111)
- SIC
- Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Health Services (8000)
- akta.pro primary industry
- Prescription-Based Digital Clinics (Condition-Specific Rx Programs) (HLALAAAD)
- akta.pro secondary industries
- Chronic Condition Medication Programs (e.g., diabetes, hypertension) with Integrated Prescribing (HLALAIAH), Virtual Pharmacy & Medication Management Integration Platforms (HLALABAL), Medication Adherence & Therapy Management Platforms (refills, reminders, MTM) (HLALAIAG)
Keywords
Where Medlinker is headquartered
LocationHeadquarters
- HQ city
- Chengdu
- HQ country
- China
- HQ region
- Asia
Offices4 records
Markets served
Medlinker business model
Business model- GTM type
- B2B and B2C
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations
Revenue model
- B2B Institutional AI Platform Licensing (MedGPT): MedGPT is licensed to hospitals (e.g., 中国电子云, 中日友好医院, 北医三院), pharmaceutical companies, and insurance companies for clinical decision support, pre-consultation systems, specialist management, and cost control applications. This is currently the primary revenue stream. Revenue is usage-based and contract-based for enterprise deployments.
- Pharmaceutical & Medical Device Digital Marketing (医联通): 医联通 (Yiliantong)精准营销平台 connects pharma and medical device companies with doctors on the platform through targeted marketing tools: doctor direct chat, online department meetings, and academic content promotion. Revenue comes from pharma company marketing spend on the platform.
- C-End Consultation Services (Free for Users): Future Doctor provides free expert consultations to C-end consumers, funded by B-end revenue streams. The free service model is a customer acquisition strategy to build scale and network effects.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Others | Free expert consultation for C-end consumers |
| Subscription | Annual | B-end enterprise licensing of MedGPT |
Go-to-market motion2 records
Distribution channels7 records
Marketing channels5 records
Medlinker product offering
Product offeringCore offering
Medlinker develops and licenses MedGPT, a proprietary medical vertical large language model that provides AI-powered disease diagnosis and treatment recommendations to hospitals, insurance companies, and pharmaceutical enterprises. Through its consumer-facing Future Doctor app (未来医生), Medlinker offers 24/7 free expert consultations with Grade 3A hospital specialists, AI-assisted triage, and integrated online-offline healthcare. The platform also operates Yiliantong (医联通), a digital marketing platform connecting pharma companies with physicians on the network.
Product overview
Medlinker operates a multi-product AI healthcare portfolio anchored by 未来医生 (Future Doctor) — the consumer-facing AI medical service app — and MedGPT, its proprietary medical large language model. MedGPT powers the core diagnostic and treatment recommendation capabilities across all platform products. The product family spans consumer-facing AI consultation (未来医生), AI-powered enterprise solutions for institutional clients (AI企业应用平台, AI医疗应用平台), insurance billing integration (保险行业解决方案), and pharmaceutical digital marketing (医联通). The platform integrates cloud imaging, cloud lab testing, IoT devices, and insurance services through third-party partnerships, covering diseases across 26 clinical disciplines, 109 subspecialties, and 30,000+ disease categories with 100,000+ medical guidelines and 800 million evidence units.
Differentiator
Problem solved
Functional benefit
Brands
- MedGPT: China's first approved generative AI medical model for disease diagnosis and treatment recommendations
- 未来医生 (Future Doctor)
- 医联通
- DoctorWorks.AI
Products and services
- Future Doctor (未来医生) Consumer-facing AI medical service mobile app providing 24/7 free expert consultation from Grade 3A hospital specialists, AI-assisted intelligent triage, and integrated online-offline healthcare including appointments, examinations, and medication delivery. Powered by MedGPT with all recommendations reviewed and signed by expert teams. Features three-tier routing (health consultation, professional diagnosis, emergency pathway) and MDT for complex cases.
- MedGPT Proprietary medical vertical large language model (LLM) and China's first CAC-approved generative AI for disease diagnosis and treatment recommendations. Features dual fast-slow system architecture to suppress hallucinations. Achieved 96% diagnostic consistency with Grade 3A attending physicians and ranked #1 in SuperCLUE medical diagnosis benchmark. Licensed to hospitals, insurance companies, and pharmaceutical enterprises.
- DoctorWorks.AI (未来医生AI工作室) AI studio product for medical professionals, integrating the MedGPT model to provide doctors with AI-powered diagnostic decision support, intelligent patient management tools, and clinical workflow assistance.
- AI Enterprise Application Platform (AI企业应用平台) B-end enterprise AI application platform leveraging MedGPT for scenarios including health consultation, pre-diagnosis, report interpretation, and patient management for pharmaceutical companies, insurance firms, and large corporations.
- AI Medical Application Platform (AI医疗应用平台) Medical institution-facing AI platform powered by MedGPT, offering clinical decision support, specialist management tools, and proactive patient health management capabilities for hospitals and healthcare organizations.
- Insurance Industry Solutions (保险行业解决方案) Integration solution connecting medical services with insurance platforms, enabling direct insurance billing for online medical consultations and prescription services, supporting medical insurance cost control.
- Yiliantong (医联通) Digital Marketing Platform China's first precision digital marketing platform for pharmaceutical and medical device companies. Connects pharma enterprises with doctors through targeted engagement tools, online academic conferences, and operational support services.
Companies that use Medlinker
Customer profileNamed customers8 records
Segments5 records
Ideal customer profiles4 records
Medlinker technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration9 records
AI capability8 records
Feature6 records
Medlinker partnerships and signals
Strategic signalPartnerships
16 partnerships are on record, tiered minor and core.
- 健康中国App ( People's Health App)minorFuture Doctor reached official cooperation with the People's Health App, expanding distribution channel for expert consultation services.
- 深圳龙岗区社区卫生服务中心 (深圳市龙岗区社区卫生服务管理中心)minor医联与深圳龙岗区社区卫生服务管理中心合作，打造全国首个基层全科医生智能体 (AI GP Agent), bringing AI-powered medical consultation to grassroots healthcare.
- 腾讯云 (Tencent Cloud) — Strategic Cloud Partnershipcore医联与腾讯云建立战略合作关系，在算力支持、工程工具和合规框架方面展开深度合作，共同推动AI医疗应用的发展。腾讯云提供底层云计算 infrastructure 支持医联MedGPT的模型训练和部署。
- 众安保险 (Zhong'an Insurance)minor医联与众安保险合作推出手术意外险，是国内首个'带病投保'产品，最高保额30万元。医联引入医生和医疗机构评价体系，与保险控费结合。
- 全景医学 (上海全景医学影像科技股份有限公司)minor医联与全景医学达成战略合作，就'云影像'业务展开合作，共同打造院外影像医疗生态体系。合作重点在肿瘤精准检查、心脑血管疾病检查等主要疾病领域。
- 宝秀兰儿童早期发展优化中心minor医联与宝秀兰中心达成战略合作，共建'婴幼儿行为神经发育专业'学科。宝秀兰中心专家集体入驻医联平台，为高危儿及有行为及神经发育相关问题的婴幼儿提供线上诊疗服务。
- 金域医学core医联与金域医学达成战略合作，共同打造慢病管理领域云检测整合服务方案。双方合作覆盖70多个病种的检测服务，覆盖36个城市，患者可预约到采样点采样或护士上门采样，最快24小时内获取检测结果。
- 北京燕化医院minor医联通过与北京燕化医院合作，实现北京地区医保支付功能，成为北京地区首个实现线上医保支付的平台型互联网医院。北京燕化医院是北京市首家开通'互联网+'医保服务的医疗机构，也是基本医疗保险A类定点医疗机构。
- 中国初级卫生保健基金会minor2019年5月，医联与中国初级卫生保健基金会共同成立了国内首支互联网医院公益基金，旨在从多个方向开展医疗公益项目，为医生和患者提供支持。
- 北京费森尤斯卡比医药有限公司minor中国医疗保健国际交流促进会肾脏病防治分会联合医联和费森尤斯卡比共同发起慢性肾脏病管理中心项目，利用互联网和AI技术对CKD患者进行全程管理。
- 正大天晴药业集团core医联与正大天晴药业集团签订战略合作协议，双方共同探索以患者为中心的慢病管理解决方案，重点围绕肿瘤、肝病、呼吸等多学科疾病领域，打造覆盖多学科疾病领域的互联网医疗新生态，为医生提供规范化患者管理，为患者提供电子处方、云药房等创新服务。
- 吉因加minor医联与吉因加达成战略合作，共建肿瘤云诊室慢病管理服务体系。合作聚焦肿瘤领域线上慢病复诊、随访管理、医患教育及产品研发。
- 呼吸家minor医联与呼吸家达成战略合作，共同探索呼吸哮喘及慢阻肺等病种领域的慢病管理。将呼吸家物联网医疗设备与医联慢病管理平台结合，打通呼吸类疾病慢病管理全流程。
- 弗吉尼亚大学附属医院 (recruiting physicians from Stanford, University of Virginia for AI study)minor医联's AI MedGPT clinical study involved collaboration with international institutions including Stanford University and University of Virginia for physician recruitment in comparative AI-vs-human doctor studies.
- 保险极客minor医联携手保险极客，打造互联网医院保险直赔模式，将在线诊疗与商业保险理赔打通。
- 银川市政府/银川互联网医院基地core医联于2017年3月获得银川互联网医院牌照，2017年8月正式入驻银川，成为国内首批互联网医院基地成员之一。银川基地是国内首个互联网医院基地。
Scale indicators10 records
Recent moves15 records
Expansion highlights7 records
Medlinker competitors and assessment
Company assessmentDirect peers
- We Doctor (微医): China's leading internet hospital and consumer telehealth platform offering online consultations, hospital appointments, and chronic disease management. Operates in the same regulatory and product category as Medlinker's Future Doctor and MedGPT-powered hospital deployments.
- Ping An Healthcare and Technology (平安好医生): Subsidiary of Ping An Group offering AI-augmented consumer telehealth, family doctor services, and B2B insurance-linked medical services. Comparable to Medlinker in combining AI consultation with insurance cost-control and consumer-facing freemium models.
- JD Health (京东健康): Online healthcare arm of JD.com providing telemedicine, prescription drug retail, and consumer health services. Overlaps with Medlinker in online consultation and chronic disease management, with a stronger retail-pharmacy footprint.
- Chunyu Doctor (春雨医生): One of China's earliest consumer telehealth apps, providing AI-assisted and physician consultation services via mobile app. Directly comparable to Future Doctor on the consumer telehealth and AI triage dimensions.
- DXY (丁香园): China's largest online professional community for physicians, plus consumer-facing health content and services. Directly comparable to Medlinker's doctor-network foundation and academic credibility with physicians.
- Hao Daifu Online (好大夫在线): Pioneer in Chinese online doctor appointment booking and expert consultation services. Directly competes with Medlinker's Future Doctor in the C-end specialist consultation category.
Broad incumbents
- Alibaba Health (阿里健康): Hong Kong-listed healthcare arm of Alibaba offering pharmaceuticals, telemedicine, and AI medical services. A broader incumbent with significant capital and ecosystem scale; competes with Medlinker across retail pharmacy, online consultation, and AI diagnostics.
- Teladoc Health: Global leader in virtual care with strong AI/clinical decision support capabilities. Useful international comparable for Medlinker's B2B MedGPT enterprise model and consumer telehealth positioning.
Emerging players
- Tencent Trusted Doctor (腾讯企鹅医生): Joint venture between Tencent and physicians to deliver online and offline medical services. Closely tied to the same Tencent investor ecosystem as Medlinker, with overlapping use cases in online consultation and primary care clinics.
- Baidu Health (百度健康): Healthcare arm of Baidu offering AI-driven medical Q&A, physician search, and chronic disease content. Competes directly with Medlinker's AI medical consultation capabilities, leveraging Baidu's general-purpose LLM.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks7 records
Key highlights7 records
Customer concentration
Medlinker compliance and trust
Trust signalCompliance4 records
Medlinker financial estimates
Financial estimateRevenue estimate
Valuation estimate
Medlinker leadership team
Management profileNumber of profiles
Profiles6 records
Medlinker subsidiaries and ownership
Company hierarchySubsidiaries5 records
Medlinker funding detail
Funding detailFunding overview
Funding rounds9 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Medlinker M&A and investment
M&A and investmentM&A1 record
Investments2 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Medlinker
What does Medlinker do?
Medlinker develops and licenses MedGPT, a proprietary medical vertical large language model that provides AI-powered disease diagnosis and treatment recommendations to hospitals, insurance companies, and pharmaceutical enterprises. Through its consumer-facing Future Doctor app (未来医生), Medlinker offers 24/7 free expert consultations with Grade 3A hospital specialists, AI-assisted triage, and integrated online-offline healthcare. The platform also operates Yiliantong (医联通), a digital marketing platform connecting pharma companies with physicians on the network.
Is Medlinker a public or private company?
Medlinker is a private company. It is classified as venture growth investor backed and is currently operating.
When was Medlinker founded?
Medlinker was founded in 2014. It employs 51 to 100 people.
Where is Medlinker based?
Medlinker is headquartered in Chengdu, China, in the Asia region.
How does Medlinker make money?
Three revenue lines are on record. B2B Institutional AI Platform Licensing (MedGPT) is the primary driver. The others are pharmaceutical & Medical Device Digital Marketing (医联通) and C-End Consultation Services (Free for Users).
Who are Medlinker's main competitors?
Direct peers on record are We Doctor (微医), Ping An Healthcare and Technology (平安好医生), JD Health (京东健康), Chunyu Doctor (春雨医生), DXY (丁香园) and Hao Daifu Online (好大夫在线). Broad incumbents are Alibaba Health (阿里健康) and Teladoc Health. Emerging players are Tencent Trusted Doctor (腾讯企鹅医生) and Baidu Health (百度健康).
Does Medlinker have an API?
No public API is recorded for Medlinker.
What industry is Medlinker in?
Medlinker's product category is AI Medical Diagnosis Software. Its primary akta.pro industry code is HLALAAAD, Prescription-Based Digital Clinics (Condition-Specific Rx Programs), with a secondary code of HLALAIAH, Chronic Condition Medication Programs (e.g., diabetes, hypertension) with Integrated Prescribing. Its NAICS code is 62111 and its SIC code is 8011.